![]() | |
| Clinical data | |
|---|---|
| Other names | 2C-B-FLY-NBOMe; NBOMe-2C-B-FLY; Cimbi-31; N-(2-Methoxybenzyl)-2C-B-FLY |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H22BrNO3 |
| Molar mass | 404.304 g·mol−1 |
| 3D model (JSmol) | |
| |
| | |
2CBFly-NBOMe, also known as NBOMe-2C-B-FLY or as Cimbi-31, is a serotonin receptor modulator of the phenethylamine, DOx, and FLY families. It was indirectly derived from the phenethylamine hallucinogen 2C-B is and related to benzodifurans like 2C-B-FLY and N-benzylphenethylamines like 25B-NBOMe.
Interactions
Pharmacology
Pharmacodynamics
2CBFly-NBOMe acts as a potent partial agonist for the 5-HT2A serotonin receptor subtype.123
Chemistry
Analogues
Analogues of 2CBFly-NBOMe include 2C-B-FLY and 25B-NBOMe, among others.
History
2CBFly-NBOMe was discovered in 2002,4 and further researched by Ralf Heim at the Free University of Berlin,5 and subsequently investigated in more detail by a team at Purdue University led by David E. Nichols.6
Society and culture
Legal status
Canada
2CBFly-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.7
United Kingdom
This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.8
United States
2CBFly-NBOMe is not an explicitly controlled substance in the United States.9 However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
2CBFly-NBOMe is a controlled substance in Vermont as of January 2016.10
References
References
- Silva ME, Heim R, Strasser A, Elz S, Dove S (January 2011). "Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor". Journal of Computer-Aided Molecular Design. 25 (1): 51–66. Bibcode:2011JCAMD..25...51S. CiteSeerX 10.1.1.688.2670. doi:10.1007/s10822-010-9400-2. PMID 21088982. S2CID 3103050.
- Ettrup A, Hansen M, Santini MA, Paine J, Gillings N, Palner M, et al. (April 2011). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging. 38 (4): 681–93. doi:10.1007/s00259-010-1686-8. PMID 21174090. S2CID 12467684.
- Hansen M (2011). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (PhD.). University of Copenhagen. Archived from the original on 2013-10-22. Retrieved 2012-11-02.
- Elz S, Klass T, Heim R, Warnke U, Pertz HH (2002). "Development of highly potent partial agonists and chiral antagonists as tools for the study of 5-HT2A-receptor mediated function". Naunyn-Schmiedeberg's Archives of Pharmacology. 365 (1 Suppl): R21–R40. doi:10.1007/s00210-002-0604-4.
- Heim R (2004). Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts (PhD.). Free University of Berlin.
- Braden MR (2007). Towards a biophysical understanding of hallucinogen action (PhD.). Purdue University. ProQuest 304838368.
- "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
- "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.
- Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
- "Regulated Drugs Rule" (PDF). Vermont Department of Health. Archived from the original (PDF) on 5 June 2016. Retrieved 14 October 2015.
